Get all your news in one place.
100's of premium titles.
One app.
Start reading
Barchart
Barchart
Kritika Sarmah

Earnings Preview: What to Expect From Gilead Sciences’ Report

Situated in Foster City, California, Gilead Sciences, Inc. (GILD) is a top biopharmaceutical company specializing in the development and commercialization of innovative therapies for diseases such as HIV, liver diseases, cancer, and inflammation. Its market cap currently stands at $114.2 billion. The company is set to announce its fiscal Q4 earnings results after the market closes on Tuesday, February 11.

Ahead of the event, analysts expect GILD to report a profit of $1.67 per share, down 2.9% from $1.72 per share in the year-ago quarter. The company surpassed Wall Street’s bottom-line estimates in three of the past four quarters and missed on another occasion. 

Sign up to read this article
Read news from 100's of titles, curated specifically for you.
Already a member? Sign in here
Related Stories
Top stories on inkl right now
One subscription that gives you access to news from hundreds of sites
Already a member? Sign in here
Our Picks
Fourteen days free
Download the app
One app. One membership.
100+ trusted global sources.